356
Participants
Start Date
December 31, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
January 31, 2012
golimumab
100 mg sc injections every 4 wks from wk 0 up to 5 yrs
Golimumab (CNTO 148); placebo
SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
golimumab
50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
Paradise Valley
Los Angeles
San Francisco
Ormond Beach
Portland
Duncansville
Houston
Edmonds
Seattle
Brookfield
La Crosse
Brussels
Diepenbeek
Leuven
Edmonton
Vancouver
Victoria
Winnipeg
St. John's
Toronto
Sainte-Foy
Helsinki
Rauma
Nantes Cedex 01 N/A
Bad Nauheim
Baden-Baden
Berlin
Erlangen
Hanover
Herne
München
Maastricht
Nijmegen
Busan
Pusan
Seoul
Kaohsiung City
Taichung
Taoyuan District
Lead Sponsor
Collaborators (1)
Schering-Plough
INDUSTRY
Centocor, Inc.
INDUSTRY